Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis

Experimental Parasitology

Volumn 121, Issue 1, 2009, Pages 29-37

  Bhardwaj, Suvercha ^a   Vasishta, R K ^a   Arora, Sunil K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Adjuvant; Immunoprophylaxis; Leishmania donovani

Indexed keywords

COMPLEMENTARY DNA; FREUND ADJUVANT; GAMMA INTERFERON; LIPID A DERIVATIVE; MONOPHOSPHORYL A; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN RA6; RECOMBINANT PROTEINS RF14; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; HAMSTER; IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; LEISHMANIA DONOVANI; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINATION; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CRICETINAE; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GRANULOMA; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPID A; LIVER; LYMPHOCYTE ACTIVATION; MALE; MESOCRICETUS; NITRITES; ORGAN SIZE; PROTOZOAN VACCINES; SPLEEN; SUPEROXIDES; VACCINES, SYNTHETIC;

ANIMALIA; CRICETINAE; LEISHMANIA DONOVANI;

EID: 57049173899     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2008.09.019     Document Type: Article

References (54)

1. Afrin F., and Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infection and Immunity 65 (1997) 2371-2377
2. Ansari N.A., Saluja S., and Salotra P. Elevated levels of interferon-γ, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clinical Immunology 119 (2006) 339-345
3. Arora S.K., Pal N.S., and Mujtaba S. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines. Experimental Parasitology 109 (2005) 163-170
4. Arora S.K., Sinha R., and Sehgal S. Use of in vitro method to assess different brands of anti-leishmanial drugs. Medical Microbiology and Immunology 180 (1991) 21-27
5. Babior B.M., and Cohen H.J. Measurement of neutrophil function: phagocytosis, degranulation, the respiratory burst and bacterial killing. In: Clinc M.J. (Ed). Methods in Hematology. Leukocyte Function vol. 3 (1981), Churchill Livingstone Inc., New York 17-18
6. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. Journal of Immunology 174 (2005) 7160-7171
7. Bhattacharya S., Ghosh S., Jhonson P.L., Bhattacharya S.K., and Majumdar S. Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events. Infection and Immunity 69 (2001) 1499-1507
8. Bretcher P.A., Wei G., Menon J.N., and Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes 'susceptible' mice resistant to Leishmania major. Science 257 (1992) 539-542
9. Burns Jr. J.M., Shreffler W.G., Benson D.R., Ghalib H.W., Badaro R., and Reed S.G. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proceedings of the National Academy of Sciences, USA 90 (1993) 775-779
10. Carvalho E.M., Bacellar O., Barral A., Badaro R., and Johnson Jr. W.D. Antigen specific immunosuppression in visceral leishmaniasis is cell-mediated. Journal of Clinical Investigation 83 (1989) 860-864
11. de Almeida M.C., Vilhena V., Barral A., and Barral-Netto M. Leishmanial infection: analysis of its first step. A review. Memorias do Instituto Oswaldo Cruz 98 (2003) 861-870
12. Friede M., Muller S., Briand J.P., Van Regenmortel M.H., and Schuber F. Induction of immune response against a short synthetic peptide antigen coupled to small neutral liposomes containing monophosphoryl lipid A. Molecular Immunology 30 (1993) 539-547
13. Garg R., Gupta S.K., Tripathi P., Naik S., Sundar S., and Dube A. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clinical and Experimental Immunology 140 (2005) 149-156
14. Ghose A.C., Haldar J.P., Pal S.C., Mishra B.P., and Mishra K.K. Serological investigations on Indian kala-azar. Clinical and Experimental Immunology 40 (1980) 318-326
15. Green S.J., Crawford R.M., Hockmeyer J.T., Meltzer M.S., and Nacy C.A. Leishmania major amastigotes initiate the l-arginine dependent killing mechanism, in IFN-γ stimulated macrophages by induction of tumor necrosis factor-α. Journal of Immunology 145 (1990) 4290-4297
16. Gupta R.K., Relyveld E.H., and Lindblad E.B. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11 (1993) 293-306
17. Holbrook T.W., Cook J.A., and Parker B.W. Immunization against L. Donovani. Glucan as an adjuvant with killed promastigotes. American Journal of Tropical Medicine and Hygiene 30 (1981) 762-768
18. Howard J.G. Immunological regulation and control of experimental leishmaniasis. International Reviews in Experimental Pathology 28 (1986) 79-116
19. Iborra S., Soto M., Carrion J., Nieto A., Fernandez E., Alonso C., et al. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infection and Immunity 71 (2003) 6562-6572
20. Kedzierski L., Zhu Y., and Handman E. Leishmania vaccines: progress and problems. Parasitology 133 (2006) 87-112
21. Marques-da-Silva E.A., Coelho E.A., Gomes D.C., Vilela M.C., Masioli C.Z., and Tavares C.A. Intramuscular immunization with p36 (LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitology Research 98 (2005) 67-74
22. Mauel J., and Behin R. Immunity: clinical and experimental. In: Peters W., and Killick-Kendrick R. (Eds). The Leishmaniasis in Biology and Medicine vol. 2 (1987), Academic Press, London, UK 31-739
23. Mayrink W., Williams P., Dacosta C.A., Magalhaes P.A., Melo M.N., Dias M., et al. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito-Santo, Brazil. Annals of Tropical Medicine and Parasitology 79 (1985) 259-269
24. McElrath M.J., Murray H.W., and Cohn Z.A. The dynamics of granuloma formation in experimental visceral leishmaniasis. Journal of Experimental Medicine 167 (1988) 1927-1937
25. Melby P.C., Chandrasekar B., Zhao W., and Coe J.E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. Journal of Immunology 166 (2001) 1912-1920
26. Melby P.C., Tryon V.V., Chandrasekar B., and Freeman G.L. Cloning of syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infection and Immunity 66 (1998) 2135-2142
27. Mielke M.E., Peters C., and Hahn H. Cytokines in the induction and expression of T-cell-mediated granuloma formation and protection in the murine model of listeriosis. Immunological Reviews 158 (1997) 79-93
28. Molano I., Alonso M.G., Miron C., Redondo E., Requena J.M., Soto M., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. Infantum. Veterinary Immunology and Immunopathology 92 (2003) 1-13
29. Murphy M.L., Cotterell S., Gorak M., Engwerda C.R., and Kaye P.M. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. Journal of Immunology 161 (1998) 4153-4160
30. Murray H.W. Effect of continuous administration of interferon-γ in experimental visceral leishmaniasis. Journal of Infectious Diseases 161 (1990) 992-994
31. Murray H.W. Granulomatous inflammation: host antimicrobial defense in the tissues in visceral leishmaniasis. In: Gallin J., Synderman R., Fearon D., Haynes B., and Nathan C. (Eds). Inflammation: Basic Principles and Clinical Correlates. third ed. (1999), Lippincott-Raven, Philadelphia 77-994
32. Murray H.W. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 45 (2001) 2185-2197
33. + T cells of naive healthy uninfected individuals. Journal of Parasitic Diseases 27 (2003) 47-52
34. Pintado V., Marti{dotless}́n-Rabadán P., Rivera M.L., Moreno S., and Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80 (2001) 54-73
35. Reed S.G., Coler R.N., and Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Reviews in Vaccines 2 (2003) 239-252
36. Richards R., Rao M., Wassef N., Glenn G., Rothwell S., and Alving C. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS, S malaria antigen. Infection and Immunity 66 (1998) 2859-2865
37. Roach T.I., Kiderlen A.F., and Blackwell J.M. Role of inorganic nitrogen oxides and tumor necrosis factor α in killing Leishmania donovani amastigotes in γ interferon-lipopolysaccharide-activated macrophages from Lshs and Lshr congenic mouse strains. Infection and Immunity 59 (1991) 3935-3944
38. Roberts M.T., Stober C.B., McKenzi A.N., and Blackwell J.M. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infection and Immunity 73 (2005) 7620-7628
39. Sambrook J., and Russel D.W. Molecular Cloning - A Laboratory Manual. third ed. (2001), Cold Spring Harbor Laboratory Press, New York
40. Sasaki S., Tsuji T., Hamajima K., Fukushima J., Ishii N., Kaneko T., et al. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infection and Immunity 65 (1997) 3520-3528
41. Scott P., Pearce E., Natovitz P., and Sher A. Vaccination against cutaneous leishmaniasis in a murine model. 1. Induction of protective immunity with a soluble extract of promastigotes. Journal of Immunology 139 (1987) 221-227
42. Shiloh M.U., MacMicking J.D., Nicholson S., Brause J.E., Potter S., Marino M., et al. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10 (1999) 29-38
43. Spitzer N., Jardim A., Lippert D., and Olafson R.W. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 17 (1999) 1298-1300
44. Squires K.E., Schreibe R.D., McElrath M.J., Rubin B.Y., Anderson S.L., and Murray H.W. Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. Journal of Immunology 143 (1989) 4244-4249
45. Stager S., Smith D.F., and Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. Journal of Immunology 165 (2000) 7064-7071
46. Stauber L.A., Franchino E.M., and Grun J. An eight day method for screening compounds against Leishmania donovani in the golden hamster. Journal of Protozoology 5 (1958) 269-273
47. Stober C.B., Lange U.G., Roberts M.T., Alcami A., and Blackwell J.M. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. Journal of Immunology 175 (2005) 2517-2524
48. Tewary P., Sukumaran B., Saxena S., and Madhubala R. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Vaccine 22 (2004) 3053-3060
49. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of National Academy of Sciences, USA 76 (1979) 4350-4354
50. Travi B.L., Osorio Y., Melby P.C., Chandrasekar B., Arteaga L., and Saravia N.G. Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp. Infection and Immunity 70 (2002) 2288-2296
51. Ulrich J.T., and Myers K.R. Monophosphoryl lipid A as an adjuvant. In: Powell M.F., and Newman M.J. (Eds). Vaccine Design: The Subunit and Adjuvant Approach (1995), Plenum Press, New York 495-524
52. Wilson M.E., Young B.M., Andersen K.P., Weinstock J.V., Metwali A., Ali K.M., et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infection and Immunity 63 (1995) 2062-2069
53. Yao Z., Foster P.A., and Gross G.J. Monophosphoryl lipid A protects against endotoxic shock via inhibiting neutrophil infiltration and preventing disseminated intravascular coagulation. Circulatory Shock 43 (1994) 107-114
54. Zaph C., Uzonna J., Beverley S.M., and Scott P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nature Medicine 10 (2004) 1104-1110